These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9839777)

  • 1. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine.
    Bialer M; Arcavi L; Sussan S; Volosov A; Yacobi A; Moros D; Levitt B; Laor A
    Epilepsy Res; 1998 Nov; 32(3):371-8. PubMed ID: 9839777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
    Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS
    Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.
    Bialer M; Sussan S; Abu Salach O; Danenberg HD; Ben-David J; Gibor Y; Laor A
    J Pharm Sci; 1995 Oct; 84(10):1160-3. PubMed ID: 8801328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single and multiple dose bioavailability study with carbamazepine 400 mg retard tablets with reference to enzyme autoinduction and circadian time differences.
    Hoffmann C; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Möritz KU; Siegmund W
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):496-503. PubMed ID: 9401830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers.
    Lake OA; Olling M; Barends DM
    Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the bioequivalence of two carbamazepine sustained-release formulations in healthy subjects.
    Schulz HU; Düsing R; Lührmann B; Frercks HJ
    Int J Clin Pharmacol Ther Toxicol; 1992 Oct; 30(10):410-4. PubMed ID: 1446959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy.
    Sennoune S; Iliadis A; Bonneton J; Barra Y; Genton P; Mesdjian E
    Biopharm Drug Dispos; 1996 Mar; 17(2):155-64. PubMed ID: 8907722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A limited sampling method for the estimation of AUC and Cmax of carbamazepine and carbamazepine epoxide following a single and multiple dose of a sustained-release product.
    Mahmood I; Chamberlin N
    Br J Clin Pharmacol; 1998 Mar; 45(3):241-6. PubMed ID: 9517367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets.
    Tothfalusi L; Speidl S; Endrenyi L
    Br J Clin Pharmacol; 2008 Jan; 65(1):110-22. PubMed ID: 17711537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
    McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR).
    Stevens RE; Limsakun T; Evans G; Mason DH
    J Pharm Sci; 1998 Dec; 87(12):1531-4. PubMed ID: 10189261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.
    Bareggi SR; Tata MR; Guizzaro A; Pirola R; Parisi A; Monza CG
    Int Clin Psychopharmacol; 1994; 9(1):9-16. PubMed ID: 8195585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of salivary drug monitoring for detecting efflux transporter overexpression.
    Fagiolino P; Vázquez M; Maldonado C; Ruiz ME; Volonté MG; Orozco-Suárez S; Lazarowski A
    Curr Pharm Des; 2013; 19(38):6701-8. PubMed ID: 23530513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
    Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
    Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
    Powell G; Saunders M; Marson AG
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approvable generic carbamazepine formulations may not be bioequivalent in target patient populations.
    Tothfalusi L; Endrenyi L
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):525-8. PubMed ID: 23611573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.